Neurocrine’s new Parkinson’s drug suffers launch delay due to Covid-19
On 27 April, Neurocrine Biosciences announced that it has received FDA approval for Ongentys (opicapone), an oral drug that is used as an add-on treatment to the standard-of-care drug, levodopa, in patients with Parkinson’s disease who experience end-of-dose motor fluctuations.
However, the company will not launch Ongentys until later in 2020, given the disruption caused by Covid-19.
Covid-19 pandemic could cause an increase in prevalence of PTSD
The Covid-19 pandemic has the potential to increase stress and anxiety, both because of the fear of infection and because of uncertainty about how the outbreak will affect people socially and economically.
After the severe acute respiratory syndrome (SARS) outbreak in 2003, front-line healthcare workers and people who were self-quarantined exhibited the symptoms of PTSD.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData